Sun Pharmaceutical Industries Ltd.
1,909.20+38.2 (+2.04%)
3 Jul, 12:00 PM
Analyst Ratings and Targets
Sun Pharmaceutical Industries Ltd. analyst ratings, buy/sell/hold recommendations and 12-month price targets from leading brokerages.
Analyst Ratings
Total recommendations
33
Analysts with Strong Buy
10
Analysts with buy
19
87.9%
87.88% of analysts have buy or strong buy on this stock implying positive street outlook.
Analysts with Strong Buy
10
Analysts with buy
19
Analysts with hold
1
Analysts with Sell
2
Analysts with Strong Sell
1
Target Price
Current market price
₹ 1,909.20
Median target price
₹ 2,070.00 (8.42%)
Highest target price
₹ 2,366.00 (23.93%)
Average target price
₹ 2,047.91 (7.27%)
Lowest target price
₹ 1,650.00 (-13.58%)
Financial Estimates
Sun Pharmaceutical Industries Ltd. analyst consensus estimates for revenue, EBITDA, PAT and EPS (consolidated) for the next 2 financial years on a rolling basis.
EPS for FY Mar 26: ₹ 53.24 /share
Estimated EPS for FY Mar 27
Median
₹ 54.80(2.93 %)
High
₹ 62.10(16.64 %)
Mean
₹ 54.54(2.45 %)
Low
₹ 40.40(-24.12 %)
Estimated EPS for FY Mar 28
Median
₹ 65.10(10.58 %)
High
₹ 86.60(27.54 %)
Mean
₹ 65.74(11.12 %)
Low
₹ 54.90(1.55 %)
BPS for FY Mar 26: ₹ 348.31 /share
Estimated BPS for FY Mar 27
Median
₹ 384.50(10.39 %)
High
₹ 421.50(21.01 %)
Mean
₹ 385.31(10.62 %)
Low
₹ 359.50(3.21 %)
Estimated BPS for FY Mar 28
Median
₹ 431.24(11.27 %)
High
₹ 488.00(18.37 %)
Mean
₹ 435.50(11.82 %)
Low
₹ 405.30(7.87 %)
Sales for FY Mar 26: ₹ 58.46 k Cr
Estimated Sales for FY Mar 27
Median
₹ 65.13 k Cr(11.41 %)
High
₹ 68.08 k Cr(16.46 %)
Mean
₹ 65.14 k Cr(11.42 %)
Low
₹ 63.50 k Cr(8.61 %)
Estimated Sales for FY Mar 28
Median
₹ 72.47 k Cr(11.34 %)
High
₹ 1.30 L Cr(49.13 %)
Mean
₹ 76.09 k Cr(14.09 %)
Low
₹ 69.91 k Cr(9.36 %)
Estimates Revision
How Sun Pharmaceutical Industries Ltd. analyst consensus for revenue and earnings has been revised over the last 12 months.
EPS revisions in the last 12 months
EPS estimate for FY end:
Mar 2027
Frequently Asked Questions
What is the analyst consensus recommendation for Sun Pharmaceutical Industries Ltd.?
The analyst consensus for Sun Pharmaceutical Industries Ltd. is Buy. Out of 33 analysts covering the stock, 29 have a Buy or Strong Buy rating (87.9%), 1 have a Hold and 3 have a Sell or Strong Sell rating.
What is the target price for Sun Pharmaceutical Industries Ltd.?
The median analyst target price for Sun Pharmaceutical Industries Ltd. is ₹ 2,070.00, with a high target of ₹ 2,366.00 and a low target of ₹ 1,650.00. The mean (average) target is ₹ 2,047.91.
How many analysts cover Sun Pharmaceutical Industries Ltd.?
33 analysts actively cover Sun Pharmaceutical Industries Ltd.: 10 Strong Buy, 19 Buy, 1 Hold, 2 Sell and 1 Strong Sell.
What is the upside or downside potential for Sun Pharmaceutical Industries Ltd. from the current price?
Based on the current market price of ₹ 1,909.20 and the median analyst target of ₹ 2,070.00, there is a 8.4% upside potential for Sun Pharmaceutical Industries Ltd. according to analyst consensus.
What is the revenue estimate for Sun Pharmaceutical Industries Ltd. for the next financial year?
Analyst consensus estimates Sun Pharmaceutical Industries Ltd.'s revenue for FY 2027 at ₹ 65.13 k Cr (+11.4% growth), with analyst estimates ranging from ₹ 63.50 k Cr (low) to ₹ 68.08 k Cr (high). Full revenue and earnings estimates are in the Financial Estimates section.
What is the EPS estimate for Sun Pharmaceutical Industries Ltd.?
The current trailing twelve month EPS of Sun Pharmaceutical Industries Ltd. is 46.20. Analyst consensus estimates EPS for FY 2027 at ₹ 54.80 per share (+2.9% growth). Forward EPS estimates are in the Financial Estimates section.
What is the BPS estimate for Sun Pharmaceutical Industries Ltd.?
Analyst consensus estimates the Book Value Per Share (BPS) of Sun Pharmaceutical Industries Ltd. for FY 2027 at ₹ 384.50 per share (+10.4% growth). BPS reflects the net asset value attributable to each share and is used to assess the stock's price-to-book valuation. Forward BPS estimates are in the Financial Estimates section.
Are analysts bullish or bearish on Sun Pharmaceutical Industries Ltd.?
Analyst sentiment on Sun Pharmaceutical Industries Ltd. leans buy: 87.9% of analysts have a Buy or Strong Buy rating. The consensus outlook is updated as brokerages revise their ratings — see the Estimates Revision section for how views have shifted.
Has the analyst consensus for Sun Pharmaceutical Industries Ltd. been revised recently?
Estimate revision history for Sun Pharmaceutical Industries Ltd. is available in the Estimates Revision section of the Forecast tab, showing how analyst consensus for revenue and earnings has changed over the past 12 months.
What is the current PE ratio of Sun Pharmaceutical Industries Ltd. compared to the target implied PE?
The current trailing PE of Sun Pharmaceutical Industries Ltd. is 39.11. Based on the median analyst target price of ₹ 2,070.00 and TTM EPS of 46.20, the target-implied forward PE is approximately 44.8x.